Navigation Links
PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
Date:9/9/2011

cides

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, challenges related to the implementation of our NYSE Amex compliance plan, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, at this point there can be no assurance that PharmAthene's rPA product candidate will be show
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
2. PharmAthene Reports Second Quarter 2008 Financial and Operational Results
3. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
4. PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008
5. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
6. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
7. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
8. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
9. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
10. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
11. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014 Stronger investment from private ... and consumer electronics will help fuel new growth ... firm IBISWorld has added a report on the ... report collection. , The Biometrics Scan Software industry ... such as fingerprint, iris, retina and face recognition ...
(Date:10/30/2014)... LONDON , October 30, 2014 ... Organovo Holdings Inc. (NYSE MKT: ONVO), Medivation Inc. (NASDAQ: ... PCYC ), Synthetic Biologics Inc. (NYSE MKT: SYN), and ... five companies can be accessed at: http://investor-edge.com/register ... Composite ended at 4,549.23, down 0.33%, the Dow Jones ...
(Date:10/30/2014)... Chicago, Illinois (PRWEB) October 30, 2014 ... Regenerative and Cellular Medicine Showcase in Chicago, leading ... and Orthopedic Surgeon, Dr. Wade McKenna presented talks ... Effectiveness and Orthopedic Surgical Applications For Stem Cells. ... of amniotic membrane and the properties of AlphaGEMS ...
(Date:10/30/2014)... Ontario (PRWEB) October 30, 2014 Spartan ... Spartan RX CYP2C19 System . It detects CYP2C19 ... non-invasive cheek swab. , The Spartan RX CYP2C19 System ... that has been approved in Canada. Due to the ... it may be used by healthcare professionals such as ...
Breaking Biology Technology:Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 2Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3
... A. How is fold amplification , ... using the Van Gelder and Eberwine technique (Van Gelder 1990) , ... polymerase , promoter for synthesis of ... at the end of mRNA sequences serves as the substrate for the , ...
... More thermostable than AMV RT and M-MLV RT , ... , Highly sensitive enzyme for ... for reverse transcribing transcripts with high , ... reverse transcriptase (RT) and , AMV RT, Ambion's HIV ...
... , Convenient format - premixed cap analog , ... RNA , 80% capping efficiency , ... , Ideal for microinjection, in vitro , ... The mMESSAGE mMACHINE High Yield , ...
Cached Biology Technology:RNA Amplification for Array Analysis 2RNA Amplification for Array Analysis 3RNA Amplification for Array Analysis 4Recombinant HIV Reverse Transcriptase 2Rapidly Synthesize Large Amounts of Capped RNA 2Rapidly Synthesize Large Amounts of Capped RNA 3Rapidly Synthesize Large Amounts of Capped RNA 4
(Date:10/29/2014)... bodies decompose, their types and numbers of bugs ... could mean the difference between a closed case ... is using a more than $866,000 U.S. Department ... examine these changing populations. The microbial communities may ... death, gender, race, socioeconomic relations and more, said ...
(Date:10/29/2014)... An innovative workflow reveals new research potential of the ... recently published article in the Biodiversity Data ... BOLD in tabular format and imported these into a ... Writting Tool (PWT). Data were used to study ... wasps from the Microgastrinae subfamily. , BOLD is originally ...
(Date:10/29/2014)... is a hormone released by the stomach and it ... as a psychoactive substance that primarily affects brain function, ... , This knowledge, combined with findings from animal studies, ... potential to stimulate alcohol craving. , Dr. Lorenzo Leggio ... that, as they had anticipated, alcohol craving was increased ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Ghrelin stimulates an appetite for drinking alcohol 2
... A Wayne State University physician is seeking a better ... disease (CMT), or inherited sensory-motor neuropathy, a disease that ... M.D., assistant professor of neurology in WSU,s School of ... CMT may be because researchers are measuring the wrong ...
... CO- It,s about living in two worlds times two, ... the University of Nebraska Medical Center in Omaha. Caplan ... Sir," about the divisions that science and national identity ... the Anaphora Literary Press of Cochran Georgia, "Welcome Home, ...
... -- MicroRNAs (miRNAs) that regulate processes including fertilization, development, ... They can be collected from routinely collected fluids such ... of factors can interfere with the accuracy of miRNA ... the Journal of Molecular Diagnostics , a group ...
Cached Biology News:Better CMT outcome measurement is Wayne State University physician's goal 2Better CMT outcome measurement is Wayne State University physician's goal 3New protocols improve detection of microRNAs for diagnosis 2New protocols improve detection of microRNAs for diagnosis 3